The Trump administration has struck a deal with EMD Serono to lower drug prices — part of a larger push from the administration to expand coverage and improve affordability for fertility services, officials announced at the White House on Thursday.
The administration’s plan has several components, including the drugmaker pledging to lower drug prices, new benefits rules to encourage employers to offer in vitro fertilization coverage outside of health insurance, and a Food and Drug Administration priority review voucher for another fertility drug not currently available in the U.S.
